Back to all Current clinical trials
Back to all Current clinical trials
GOLSEEK-2 - Golcadomide plus Rituximab for Follicular Lymphoma
Patients newly diagnosed with advanced follicular lymphoma with be randomised to standard treatment or Golcadomide and Rituximab. Will be 1:1:1 as will be 2 doses of Golcadomide.
- Category
-
Trial status
Active, not recruiting
-
Trial phase
Phase 2 Drug TrialEarly stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
- Registry listing
-
ERM Project ID
111193
Trial contact details
-
Contact person
Jeremy Salas
-
Phone
(07) 3163 2128
What you need to know
Inclusion
- Histologically confirmed follicular lymphoma as per standards
- No prior systemic treatment for follicular lymphoma
- Needs treatment as per investigator
- Measurable disease
Exclusion
- Transformed lymphoma
- CNS involvement
- Other subtype of lymphoma
What is involved for me?
Days 1 -14 Golcadomide plus rituximab for 12 cycles (1 cycle 4 weeks) - then maintenance rituximab - weekly visit first cycle then 2 weekly for cycle 2 then monthly
6 cycles of chemo if this arm.
Regular scanning every 12 weeks
Completion questionnaires monthly first 12 months then every 16 weeks.
